

CLAIMS

1. An immunoglobulin single variable domain (ISVD) that specifically binds to human aggrecan represented by SEQ ID NO: 125, that comprises 4 framework regions FR1 to FR4, respectively and 3 complementarity determining regions CDR1 to CDR3, respectively, wherein the ISVD is chosen from the group of ISVDs, wherein:
 - CDR1 is SEQ ID NO: 24, CDR2 is SEQ ID NO: 42, and CDR3 is SEQ ID NO: 60;
 - CDR1 is SEQ ID NO: 25, CDR2 is SEQ ID NO: 43, and CDR3 is SEQ ID NO: 61; and
 - CDR1 is SEQ ID NO: 27, CDR2 is SEQ ID NO: 45, and CDR3 is SEQ ID NO: 63.
2. The ISVD according to claim 1, wherein said ISVD is chosen from the group consisting of ISVDs with SEQ ID NOs: 5, 6, 8 and 116-117.
3. The ISVD according to claim 1 or 2, wherein said ISVD has more than 80% sequence identity with any one of SEQ ID NOs: 5, 6, 8 and 116-117.
4. A polypeptide comprising at least one ISVD according to any one of claims 1-3.
5. The polypeptide according to claim 4 that comprises at least two ISVDs according to any one of claims 1-3.
6. The polypeptide according to claim 5, wherein said at least two ISVDs are independently chosen from the group consisting of SEQ ID NOs: 5, 6, 8 and 116-117.
7. The polypeptide according to any one of claims 4-6 further comprising at least one further ISVD, wherein said at least one further ISVD binds to a member of the serine protease family, cathepsins, matrix metalloproteinases (MMPs)/Matrixins or A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS).

8. The polypeptide according to any one of claims 4-7, wherein said polypeptide further comprises a serum protein binding moiety or a serum protein.
9. A construct that comprises an ISVD according to any one of claims 1-3 or a polypeptide according to any one of claims 4-8, and which further comprises one or more other groups, residues, moieties or binding units.
10. A composition comprising at least one ISVD according to any one of claims 1-3, a polypeptide according to any one of claims 4-8, or a construct according to claim 9.
11. The composition according to claim 10, the ISVD according to any one of claims 1-3, the polypeptide according to any one of claims 4-8, or the construct according to claim 9 for use as a medicament.
12. The composition according to claim 10, the ISVD according to any one of claims 1-3, the polypeptide according to any one of claims 4-8, or the construct according to claim 9 for use in the prevention or treatment of arthropathies and chondrodystrophies; arthritic disease such as osteoarthritis, rheumatoid arthritis, gouty arthritis, psoriatic arthritis; traumatic rupture or detachment, achondroplasia, costo-chondritis, Spondyloepimetaphyseal dysplasia, spinal disc herniation, lumbar disk degeneration disease, degenerative joint disease, and relapsing polychondritis.
13. Use of the composition according to claim 10, the ISVD according to any one of claims 1-3, the polypeptide according to any one of claims 4-8, or the construct according to claim 9 in the manufacture of a medicament for the prevention or treatment of arthropathies and chondrodystrophies; arthritic disease such as osteoarthritis, rheumatoid arthritis, gouty arthritis, psoriatic arthritis; traumatic rupture or detachment, achondroplasia, costo-chondritis, Spondyloepimetaphyseal dysplasia, spinal disc herniation, lumbar disk degeneration disease, degenerative joint disease, and relapsing polychondritis.